Fidasimtamab
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity[1].
Product Specifications
CAS Number
[2377419-89-9]
Product Name Alternative
IBI-315; BH2950
UNSPSC
12352203
Target
EGFR; PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/fidasimtamab.html
Purity
95.00
Solubility
10 mM in DMSO
Smiles
[Fidasimtamab]
Molecular Weight
(144.62 kDa)
References & Citations
[1]Shijie Jin, et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther. 2022 Feb 7;7 (1) :39.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Explore Other Products
Browse additional items from our catalog
Ppm1k sgRNA CRISPR Lentivector (Rat) (Target 1)
![Mouse Monoclonal Ki67/MKI67 Antibody [Biotin]](https://cdn.genprice.uk/genprice/uk/genprice5.webp)